InvestSMART

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.039 0.003 (7.14%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$21 Appendix 2A 14 May 2021 5:07PM $0.310 $0.039 fallen by 87.42%
$21 Proposed issue of Securities - IMU 14 May 2021 5:05PM $0.310 $0.039 fallen by 87.42%
$21 Appendix 2A 7 May 2021 6:18PM $0.260 $0.039 fallen by 85%
$21 Proposed issue of Securities - IMU 7 May 2021 6:09PM $0.260 $0.039 fallen by 85%
$21 Appendix 2A 29 Apr 2021 6:10PM $0.195 $0.039 fallen by 80%
$21 Proposed issue of Securities - IMU 29 Apr 2021 6:05PM $0.195 $0.039 fallen by 80%
$21 Prestigious Research Journal Publish HER-Vaxx Phase 1B Data 29 Apr 2021 10:15AM $0.188 $0.039 fallen by 79.20%
$21 Appendix 4C - quarterly 23 Apr 2021 1:50PM $0.193 $0.039 fallen by 79.74%
$21 Imugene announces clinical milestone for HER-Vaxx 21 Apr 2021 9:37AM $0.185 $0.039 fallen by 78.92%
$21 Appendix 2A 19 Apr 2021 5:15PM $0.195 $0.039 fallen by 80%
$21 Proposed issue of Securities - IMU 19 Apr 2021 5:09PM $0.195 $0.039 fallen by 80%
$21 Imugene Oncolytic Virus Presentation at AACR 2021 Meeting 12 Apr 2021 8:41AM $0.180 $0.039 fallen by 78.33%
$21 Imugene HER-Vaxx Presentation at AACR 2021 Meeting 12 Apr 2021 8:37AM $0.180 $0.039 fallen by 78.33%
$21 Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX 7 Apr 2021 9:23AM $0.130 $0.039 fallen by 70%
$21 Appendix 2A 1 Apr 2021 5:35PM $0.120 $0.039 fallen by 67.50%
$21 Proposed issue of Securities - IMU 1 Apr 2021 4:56PM $0.120 $0.039 fallen by 67.50%
$21 S&P DJI Announces March 2021 Quarterly Rebalance 12 Mar 2021 5:02PM $0.110 $0.039 fallen by 64.55%
$21 Appendix 3G 12 Mar 2021 5:00PM $0.110 $0.039 fallen by 64.55%
$21 Imugene to Present Oncolytic Virus Data at AACR21 Meeting 11 Mar 2021 9:43AM $0.100 $0.039 fallen by 61%
$21 Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting 11 Mar 2021 9:29AM $0.100 $0.039 fallen by 61%
$21 Half Yearly Report and Accounts 26 Feb 2021 2:46PM $0.105 $0.039 fallen by 62.86%
$21 Appendix 2A 23 Feb 2021 5:17PM $0.105 $0.039 fallen by 62.86%
$21 Proposed issue of Securities - IMU 23 Feb 2021 5:14PM $0.105 $0.039 fallen by 62.86%
$21 Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial 12 Feb 2021 8:41AM $0.100 $0.039 fallen by 61%
$21 Appendix 2A 3 Feb 2021 7:06PM $0.098 $0.039 fallen by 60.20%

626 - 650 of 1204 results

Page 26 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.